Proactive Investors - Run By Investors For Investors

Scientists make major breakthrough with ANGLE’s Parsortix liquid biopsy system

It had previously been thought that brain cancers couldn’t be traced by ANGLE’s Parsortix system, but a team of Scientists has disproved that theory
blood
Parsortix works by detecting and capturing circulating tumour cells in the bloodstream

Researchers have shown that ANGLE PLC’s (LON:AGL) Parsortix liquid biopsy system can be used to identify people with glioblastoma – an aggressive type of brain cancer.

Parsortix detects and captures circulating tumour cells (CTCs), which provide the tell-tale signs of cancer and their capture can allow doctors to more accurately assess treatment options.

READ: ANGLE on track to conclude FDA study by year-end

It had previously been thought that clusters of CTCs in brain cancers would not pass through the blood-brain barrier meaning ANGLE’s system wouldn’t have been able to detect them.

But a team of scientists from the University of Basel in Switzerland has disproved that theory, showing that as well as singular CTCs, clusters of CTCs will pass through the blood-brain barrier and can be harvested for analysis using the Parsortix system.

“The glioblastoma work is a further example of ground breaking research being undertaken by a Parsortix customer in addition to ANGLE's own efforts to commercialise the Parsortix system,” said chief executive Andrew Newland.

“University of Basel and their collaborators are working on the application of this approach for the treatment of glioblastoma patients and we look forward to reporting further developments in due course.”

Shares rose 5.2% in early deals on Tuesday to 48.9p.

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
pills
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use